{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:26:17Z","timestamp":1770960377710,"version":"3.50.1"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ijcard.2022.11.027","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T11:00:34Z","timestamp":1668855634000},"page":"419-420","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Trends in ACEi and ARB expenditure: Compelling case for competition in generic drug markets"],"prefix":"10.1016","volume":"370","author":[{"given":"Jonathan A.","family":"Batty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlous","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2022.11.027_bb0005","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.ijcard.2012.10.007","article-title":"The past, present and future of renin\u2013angiotensin aldosterone system inhibition","volume":"167","author":"Mentz","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2022.11.027_bb0010","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/1468-0009.12517","article-title":"The evolution of supply and demand in markets for generic drugs","volume":"99","author":"Frank","year":"2021","journal-title":"Milbank Q."},{"key":"10.1016\/j.ijcard.2022.11.027_bb0015","first-page":"6","article-title":"Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice","author":"Fuentes","year":"2018","journal-title":"Pharmacy (Basel)."},{"key":"10.1016\/j.ijcard.2022.11.027_bb0020","first-page":"671","article-title":"ACE inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008","volume":"16","author":"Bian","year":"2010","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.ijcard.2022.11.027_bb0025","article-title":"The utilization, expenditure, and price of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the US Medicaid programs: trends over a 31\u00a0year period","author":"Almadfaa","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2022.11.027_bb0030","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2022.11.027_bb0035","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13643-021-01802-6","article-title":"Meta-analysis of the association between angiotensin pathway inhibitors and COVID-19 severity and mortality","volume":"10","author":"Fernando","year":"2021","journal-title":"Syst. Rev."},{"key":"10.1016\/j.ijcard.2022.11.027_bb0040","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/HJH.0000000000002450","article-title":"Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?","volume":"38","author":"Esler","year":"2020","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ijcard.2022.11.027_bb0045","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/CRD.0000000000000323","article-title":"Nitrosamine impurities in angiotensin receptor blockers","volume":"28","author":"Shephard","year":"2020","journal-title":"Cardiol. Rev."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527322017144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527322017144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T21:03:02Z","timestamp":1759093382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527322017144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":9,"alternative-id":["S0167527322017144"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.11.027","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in ACEi and ARB expenditure: Compelling case for competition in generic drug markets","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.11.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.10.152","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}